VIVAPHARMA
ActiveSummary
VIVAPHARMA has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €126,780 and a net result of €118,241. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 68% of 5,017 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
12-01
Gazette deed
Resignation: Azzam Moussa (director)Appointment: Turki Eya (director) · Director discharge4 facts ▸
- General meeting, 22-12-2025
- Director resignation, Azzam Moussa (director)
- Director appointment, Turki Eya (director)
- Director discharge, Azzam Moussa
05-07
Gazette deed
Resignations: Nina MAMAGHANI (director) and Sophie GYSEMBERG (director)Appointment: Moussa AZZAM (director) · Director discharge7 facts ▸
- General meeting, 31-05-2024
- Director resignation, Nina MAMAGHANI (director)
- Director resignation, Sophie GYSEMBERG (director)
- Director discharge, Nina MAMAGHANI
- Director discharge, Sophie GYSEMBERG
- Director appointment, Moussa AZZAM (director)
- Board meeting, “administrateur, ensuite” (deed in French)
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 2 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.